SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency

Respiratory Medicine
Susan SorrellsJaume Ayguasanosa

Abstract

Alpha1-antitrypsin deficiency (AATD) is an underdiagnosed genetic disorder that results in early-onset emphysema due to low serum levels of alpha1-proteinase inhibitor (alpha1-PI), leading to increased activity of tissue-damaging neutrophil elastase. Clinical outcomes of AATD may be improved by administering alpha1-PI augmentation therapy. Here, we describe the design of the ongoing Study of ProlAstin-c Randomized Therapy with Alpha-1 augmentation (SPARTA), a phase 3 trial designed to evaluate progression of lung tissue loss in patients with severe AATD receiving human alpha1-PI (Prolastin(®)-C) versus placebo, using whole-lung computed tomography (CT) densitometry. SPARTA is a randomized, placebo-controlled trial assessing the efficacy and safety of two separate doses of Prolastin-C (60 and 120 mg/kg) administered weekly over 3 years in patients aged 18-70 years with a diagnosis of AATD and clinical evidence of pulmonary emphysema. The primary measure of efficacy (change from baseline whole-lung 15th percentile lung density [PD15]) will be determined by CT lung densitometry measured at total lung capacity. Secondary efficacy variables will be the evaluation of severe chronic obstructive pulmonary disease exacerbations, as defi...Continue Reading

References

Mar 1, 1986·Chest·J LiebermanA Sastre
Apr 23, 1987·The New England Journal of Medicine·M D WewersR G Crystal
Dec 1, 1995·American Journal of Respiratory and Critical Care Medicine·A YoshiokaY Kawakami
Mar 13, 2001·Chest·M WenckerUNKNOWN Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen
Jul 29, 2003·The European Respiratory Journal·L M FabbriUNKNOWN GOLD Scientific Committee
Feb 2, 2008·The European Respiratory Journal·M CazzolaUNKNOWN European Respiratory Society Task Force on outcomes of COPD

❮ Previous
Next ❯

Citations

Aug 27, 2016·Annals of the American Thoracic Society·Matthias Griese, Gerhard Scheuch
Nov 9, 2016·The Journal of Pharmacology and Experimental Therapeutics·Boris M BaranovskiEli C Lewis
Nov 5, 2016·Expert Review of Respiratory Medicine·Maria Paula Henao, Timothy J Craig
Oct 27, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Haitham S Al Ashry, Charlie Strange
Jun 11, 2019·Drugs & Aging·Diana CrossleyElizabeth Sapey
Sep 26, 2019·Expert Opinion on Investigational Drugs·Anita Pye, Alice M Turner
Sep 21, 2016·The Cochrane Database of Systematic Reviews·Peter C Gøtzsche, Helle Krogh Johansen
Sep 22, 2018·The European Respiratory Journal·Timm GreulichUNKNOWN RAPID Trial Group
Jul 29, 2020·Frontiers in Pharmacology·Srinu TumparaSabina Janciauskiene
Aug 9, 2020·Journal of Clinical Medicine·José Luis López-CamposCandelaria Caballero Eraso
Oct 30, 2020·Pharmaceutics·Wanling LiangJenny K W Lam
Dec 29, 2020·Therapeutics and Clinical Risk Management·Mark QuinnAlice M Turner
Aug 20, 2021·Therapeutic Advances in Chronic Disease·Igor Barjaktarevic, Michael Campos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.